1 / 18

Background

Effects of Physiologic Testosterone Supplementation on Fat Mass and Distribution in HIV-Infected Men with Abdominal Obesity. CM Shikuma 1 , RA Parker 2 , F Sattler 3 , B Alston 4 , R Haubrich 5 , T Umbleja 2 , S Bhasin 6 , for the AIDS Clinical Trials Group Protocol A5079 Study Team

feng
Download Presentation

Background

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Effects of Physiologic Testosterone Supplementation on Fat Mass and Distribution in HIV-Infected Men with Abdominal Obesity CM Shikuma1, RA Parker2, F Sattler3, B Alston4, R Haubrich5, T Umbleja2, S Bhasin6, for the AIDS Clinical Trials Group Protocol A5079 Study Team 1 University of Hawaii, Honolulu, HI; 2 Harvard School of Public Health, Boston, MA; 3 University of Southern California, Los Angeles, CA 4 Division of AIDS, NIAID, Bethesda MD; 5 University of California, San Diego, San Diego, CA; 6 Boston University, Boston MA

  2. Background • Abdominal obesity is commonly seen in HIV+ men following use of potent antiretroviral therapy • In the general population, increases in visceral adipose tissue [VAT] have been linked to increased risk of cardiovascular disease and type 2 diabetes1 1Sowers JR, Am J of Med 115 (8A):37s-41s

  3. Background • Testosterone replacement in hypogonadal HIV- middle-age men decrease visceral fat, increase insulin sensitivity and lower triglyceride and cholesterol levels 1,2,3 • Few studies have addressed the effects of testosterone therapy on body fat distribution in HIV+ men • Specifically, the effect of therapy on visceral fat in HIV+ men with abdominal obesity is unknown. 1Marin P et al 1992, Int J Obes Relat Metab Disord 16:991-997; 2Marin P et al Obes Res 1993, 1:245-251; 3Rebuffe-Scrive M Int J Obes 1991, 15:791-5

  4. A5079 • Phase III, prospective, multicenter, randomized, placebo-controlled, double-blind study • Objective • to evaluate whether change in visceral fat cross-sectional area by CT is greater with testosterone replacement than with placebo in HIV+ men with abdominal obesity and mildly to moderately reduced serum testosterone levels

  5. Methods • Study Population: HIV+ male subjects: • Abdominal obesity • waist-to-hip ratio >0.95 or mid-waist circumference > 100 cm • Mildly to moderately reduced testosterone (T) levels • serum total T 125-400 ng/dL, or • if serum total T > 400 ng/dL then bioavailable T < 115 ng/dLby ammonium sulfate precipitation method or free T < 50 pg/mLby equilibrium dialysis • Stable potent antiretroviral regimen for at least 3 months prior to entry, and plasma HIV RNA <10,000 copies/mL

  6. A5079 Schema Double-Blind phase Open-Label phase 10 gm testosterone gel daily vs placebo 10 gm testosterone gel daily 24 wk 24 wk Wk 48 Wk 0 Wk 12 Wk 24 Wk 36 CT DEXA Body Cir CT DEXA Body Cir CT DEXA Body Cir Body Cir CT DEXA Body Cir

  7. Statistical Methods • Intent-to-treat approach with last-value-carried-forward • Significance of changes over time within a treatment group was tested using a Wilcoxon Signed Rank test • Comparison between groups was tested using a Wilcoxon Rank Sum test

  8. RESULTS: Baseline Demographic and HIV Related Variables aKruskal-Wallis; bExact Test for RxC Tables; cFisher’s Exact Test

  9. Baseline Body Composition Entries are medians, unless otherwise indicated. *Wilcoxon Rank Sumtest

  10. Changes in Safety Measures during Blinded Phase Table entries are median values of change *Change from baseline p=0.05; +Change from baseline p<0.001

  11. Percent Change over 24 weeks in CT Measures (ITT) P<0.001 * P=0.04 P=0.76 8.1% 4.3% 3.1% -1.5% 0.3% -7.2% * VAT SAT Total Abd Fat Entries within bars are median values of change; *Change in within arm differences p<0.05

  12. Percent Change over 24 Weeks in DEXA Measures (ITT) p=<0.001 p=<0.001 * * P<0.001 p=0.02 4.6% 4.5% * 3.8% 1.3% -0.3% -7.9% -10.1% -9.9% * * * Trunk Extremity Total Lean Fat Fat Fat Tissue Entries within bars are median values of change; *Change in within arm differences are p<0.05

  13. Absolute Change over 24 weeks in DEXA Measures (ITT) Entries are median values

  14. Change over 24 weeks in Waist and Waist/Hip Ratio Waist Circumference (cm) Waist to Hip Ratio P=0.03 P=0.04 -0.2 0.00 -2.1 -0.02 * * Entries are median values; *Change in within arm differences are p<0.05

  15. Summary and Conclusions • Testosterone replacement over 24 weeks in HIV+ men with abdominal obesity and low testosterone levels did not result in any significant change in the primary endpoint of abdominal visceral fat content by CT • Testosterone replacement was however associated with a decrease in subcutaneous fat and increase in lean body mass

  16. Summary and Conclusions • Ten grams of testosterone gel applied topically once daily was safe and associated with a low frequency of adverse events • Analyses of testosterone, other hormonal levels, insulin and lipid values are pending and may provide insight into the results of this study

  17. Acknowledgements • A5079 Protocol Team • Pharmaceutical Co-sponsor: Solvay Pharmaceuticals, Inc • ACTG Participating Sites: Bellevue Hosp Cntr, Drew Med Cntr, UCSD, Pittsburgh, LAC/USC Med Cntr, U Minnesota, U Nebraska Med Cntr, Washington U, U Cincinnati, Indiana U, Wishard Mem Hsp, Northwestern, Rush Presbyterian/ St. Luke’s, U of Maryland, Univ. Hawaii, U Puerto Rico, U Colorado, U Pennsylvania • Quest Diagnostics • Division of AIDS, NIAID, NIH

  18. Acknowledgements • Patient volunteers Thank you

More Related